Albumin and creatinine tests market seen doubling by 2030

The market for albumin and creatinine tests reached $3.6 billion in 2025 and is projected to rise to $9.65 billion by 2030, according to The Business Research Company. Growth is being driven by rising chronic kidney disease cases, broader diagnostic adoption, and automation in urine testing.

Why it matters: - Albumin and creatinine tests are a core tool for assessing kidney health and spotting protein leakage in urine. - The market’s rapid expansion reflects rising demand for earlier kidney disease detection and better monitoring. - Growth in chronic kidney disease, diabetes, high blood pressure and obesity is increasing the need for testing.

What happened: - The Business Research Company published its Albumin and Creatinine Tests Global Market Report 2026 on Oct. 30, 2026. - The report values the global market at $3.6 billion in 2025. - The report forecasts the market will reach $4.4 billion in 2026. - The report projects the market will climb to $9.65 billion by 2030. - The report includes market-size estimates, trends, forecasts and regional analysis.

The details: - Albumin and creatinine testing combines two measurements to give a more precise view of kidney function. - The albumin-to-creatinine ratio helps account for hydration-driven changes in creatinine. - The ratio helps providers assess protein leakage in urine more clearly. - Historical growth has been supported by limited point-of-care testing devices, continued use of manual urine dipstick methods and expanded hospital and diagnostic lab infrastructure. - The report points to advanced urine analyzers, automated lab systems, glycated albumin testing and diagnostic reagent development as major growth drivers ahead. - Key trends include wider use of point-of-care tests, stronger demand for automated analyzers, growth in microalbumin test kits for early detection and improvements in colorimetric and immunoassay reagents. - Standardized calibration and control methods are also improving test accuracy. - North America held the largest market share in 2025. - Asia-Pacific is expected to grow the fastest over the forecast period. - The report also covers South East Asia, Western and Eastern Europe, South America, and the Middle East and Africa. - The 2026 report adds market attractiveness scoring, total addressable market analysis, company scoring matrices, Excel-based forecasting dashboards, market hotspot infographics, and updated graphics and tables.

Between the lines: - The market is moving from basic screening toward more automated and standardized testing. - That shift suggests diagnostics buyers are prioritizing speed, accuracy and early detection. - The strongest regional growth outlook appears to be in Asia-Pacific, where healthcare expansion and disease burden can reinforce demand. - The report’s emphasis on reagent innovation and automation signals a competitive market focused on workflow efficiency as well as clinical performance.

What's next: - The market is expected to keep expanding through 2030 as kidney disease screening becomes more routine. - Diagnostic manufacturers are likely to compete on automation, test accuracy and early-detection products. - More information and the full report are available online.

The bottom line: - Albumin and creatinine testing is shifting from a niche diagnostic segment to a fast-growing global market tied closely to chronic kidney disease screening.